Condition: Myasthenia Gravis · Autoimmune Diseases of the Nervous System · Neuromuscular Junction Diseases · Sponsor: Assiut University
This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.
This description comes directly from the study's public registry record.
Nourelhoda AA Haridy, Lecturer · 01063981139 · nourelhodaahmed@aun.edu.eg
Eman MH Khedr, Professor · 010058506632 · Emankhedr99@yahoo.com
Always discuss trial participation with your own doctor first.
| Assiut University | Asyut, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05214612